Table 3. Expenditures and changes in budget for GDMT and GDMT + Empagliflozin (MYR).
| Events | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Total | Annual Average | Total difference, (%)1 |
Annual difference, (%)2 |
|---|---|---|---|---|---|---|---|---|---|
| Guideline Directed Medical Therapy (GDMT) | |||||||||
| Drug acquisition | 124,889,758 | 190,298,341 | 254,415,341 | 317,286,843 | 378,957,608 | 1,265,847,893 | 253,169,578 | ||
| Adverse event | 587,326 | 894,926 | 1,196,453 | 1,492,123 | 1,782,145 | 5,952,975 | 1,190,595 | ||
| Cardiovascular death | 160,413,499 | 244,426,952 | 326,781,442 | 407,536,164 | 486,748,609 | 1,625,906,669 | 325,181,333 | ||
| HF hospitalisation | 130,229,905 | 198,435,287 | 265,293,858 | 330,853,675 | 395,161,413 | 1,319,974,139 | 263,994,827 | ||
| Outpatient care | 160,629,128 | 244,755,512 | 327,220,703 | 408,083,976 | 487,402,899 | 1,628,092,220 | 325,618,444 | ||
| Renal composite outcome | 26,916,937 | 41,014,159 | 54,833,013 | 68,383,430 | 81,675,057 | 272,822,597 | 54,564,519 | ||
| Total | 603,666,554 | 919,825,181 | 1,229,740,812 | 1,533,636,213 | 1,831,727,733 | 6,118,596,495 | 1,233,719,299 | ||
| Guideline Directed Medical Therapy (GDMT) + Empagliflozin | |||||||||
| Drug acquisition | 133,500,440 | 210,009,258 | 289,599,299 | 361,264,890 | 431,591,987 | 1,425,965,876 | 285,193,175 | 160,117,983 (12.65%) |
32,023,596 (2.53%) |
| Adverse event | 598,583 | 920,790 | 1,242,757 | 1,550,296 | 1,852,091 | 6,164,519 | 1,232,9903 | 211,543 (3.55%) |
42,308 (0.71%) |
| Cardiovascular death | 159,247,502 | 241,796,928 | 322,144,334 | 401,863,672 | 480,094,095 | 1,605,146,533 | 321,029,306 | -20,760,135 (-1.28%) |
-4,152,027 (-0.26%) |
| HF hospitalisation | 126,206,419 | 189,266,601 | 248,988,898 | 310,604,851 | 371,070,005 | 1,246,136,776 | 249,227,355 | -73,837,362 (-5.59%) |
-14,767,472 (-1.12%) |
| Outpatient care | 160,629,128 | 244,790,919 | 327,335,974 | 408,340,058 | 487,831,233 | 1,628,927,314 | 325,785,462 | 835,093 (0.05%) |
167,018 (0.01%) |
| Renal composite outcome | 25,649,306 | 38,122,383 | 49,685,880 | 61,981,380 | 74,047,237 | 249,486,188 | 49,897,237 | -23,336,409 (-8.55%) |
-4,667,281 (-1.71%) |
| Total Budget | 605,831,382 | 924,906,882 | 1,238,997,146 | 1,545,605,149 | 1,846,486,649 | 6,161,827,209 | 1,232,365,441 | ||
| Annual Budget Impact 3 | 2,164,827 | 5,081,700 | 9,256,334 | 11,968,935 | 14,758,916 | 43,230,713 | 8,646,142 | 0.71% | 0.14% |
1 Total difference is defined as the difference between GDMT and GDMT + Empagliflozin over the 5 years.
2 Annual difference is defined as the average of the total difference between GDMT and GDMT + Empagliflozin over the 5 years.
3 Annual budget impact describes the total additional cost required each year for GDMT + Empagliflozin when compared with GDMT.